Neogenomics INC (NEO) — 10-Q Filings
All 10-Q filings from Neogenomics INC. Browse 4 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (4)
-
NeoGenomics Revenue Up, But Losses Widen Amid Impairment Charges
— Oct 28, 2025 Risk: high
NEOGENOMICS INC reported a significant increase in net revenue for the three months ended September 30, 2025, reaching $187.8 million, up from $167.8 million in -
NeoGenomics Q1 2025 Financials Filed
— Apr 29, 2025 Risk: medium
NeoGenomics Inc. reported its first quarter results for the period ending March 31, 2025. The company's filing details its financial position, including common -
NeoGenomics Q2 2024: $235.7M Revenue, $36.7M Net Loss
— Jul 30, 2024 Risk: medium
NeoGenomics Inc. reported its Q2 2024 results, with total revenue for the six months ended June 30, 2024, reaching $235.7 million. The company's net loss for th -
NeoGenomics, Inc. Reports First Quarter 2024 Financial Results
— Apr 30, 2024 Risk: medium
NEOGENOMICS INC (NEO) filed a Quarterly Report (10-Q) with the SEC on April 30, 2024. Revenue for the three months ended March 31, 2024, was $126.9 million. Net
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX